Last Updated: April 30, 2026

Profile for Philippines Patent: 12017502092


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Philippines Patent: 12017502092

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
10,195,160 May 19, 2036 Organon Llc VTAMA tapinarof
10,426,743 May 19, 2036 Organon Llc VTAMA tapinarof
11,458,108 May 19, 2036 Organon Llc VTAMA tapinarof
11,612,573 May 19, 2036 Organon Llc VTAMA tapinarof
11,617,724 May 19, 2036 Organon Llc VTAMA tapinarof
11,622,945 May 19, 2036 Organon Llc VTAMA tapinarof
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Patent PH12017502092: Scope, Claims, and Landscape Overview

Last updated: February 24, 2026

What are the key aspects of patent PH12017502092's scope and claims?

Patent PH12017502092 was filed in the Philippines and pertains to a pharmaceutical invention, likely involving a novel compound, formulation, or method. Based on public records, the patent aims to secure exclusive rights for specific therapeutic compounds or processes in the management of certain medical conditions.

Scope of the Patent

The patent's scope encompasses:

  • Chemical Composition: The patent claims specific molecules, derivatives, or formulations. These could include active pharmaceutical ingredients (APIs) with unique structural modifications.
  • Methods of Production: Processes to synthesize the compounds, including any novel steps or yields.
  • Therapeutic Use: The indication areas, such as treatment of particular diseases or conditions, are explicitly outlined.
  • Dosage Forms: Delivery mechanisms like tablets, injections, or transdermal applications.
  • Combination Therapies: If applicable, claims may include combinations with other drugs to enhance efficacy or reduce side effects.

Claims Analysis

The claims form the core legal protection and are categorized as independent or dependent:

  • Independent Claims: Usually broad, covering the novel compound or process itself. For example, a claim may cover "A compound with the structure of X or a salt or ester thereof," or a method of synthesizing such compounds.

  • Dependent Claims: Narrower, specifying particular embodiments, such as specific substituents, formulations, or use cases.

The typical scope likely covers:

  • Chemical entities with specified structural features.
  • Particular formulations with excipients.
  • Manufacturing processes with defined steps.
  • Use in treating designated illnesses, such as cancer, infectious diseases, or metabolic disorders.

Example (Hypothetical):

Independent claim: A pharmaceutical composition comprising a compound of formula I, wherein the substituents are as defined, for use in treating [Condition].*

Dependent claim: The composition of claim 1, wherein the compound is a salt or ester.

Patent Claims Strengths and Gaps

  • Strengths: Likely to protect specific molecules and their use, provided the claims are sufficiently broad.
  • Gaps: Broad claims risk being challenged for novelty and inventive step; narrow claims may limit enforcement.

What does the patent landscape look like in the Philippines for similar drugs?

Regional and International Patent Landscape

The Philippines, as a signatory to the Patent Cooperation Treaty (PCT), allows for patent filings that can cover multiple jurisdictions. The landscape includes:

  • Major Pharmaceutical Innovators: Companies like Pfizer, Roche, and Sanofi hold patents covering similar drug classes in Asia.
  • Patent Families and Priority: Many drugs are protected by extensive patent families. For example, a compound patented broadly in the US or EU potentially faces local equivalents or challenges in the Philippine jurisdiction.

Similar Patent Filings in Southeast Asia

  • Global Patent Filings: Drugs like imatinib, trastuzumab, and checkpoint inhibitors have patents or patent families filed across countries including the Philippines.
  • Local Law Specifics: The Intellectual Property Office of the Philippines (IPOPHL) follows standard practices aligned with the ASEAN patent examination guidelines.

Patent Challenges and Competition

  • Legal Challenges: Patent validity might be scrutinized for novelty or inventive step, especially for known compounds or methods.
  • Generic Competition: Once patents expire or are invalidated, local generics can enter the market, leading to price competition.
  • Research and Development (R&D) Trends: Countries are increasingly filing patents related to biosimilars, drug delivery systems, and combination therapies.

Out-licensing and Patent Portfolio Strategies

  • Pharmaceutical Companies: Focus on extending patent life via secondary filings, formulation claims, or combination therapies.
  • Local Entities: Often license patents from international firms or file provisional applications targeting specific niches.

What are recent patent policies affecting the Philippines drug patent landscape?

  • Philippine Patent Law: Based on RA 8293 (Intellectual Property Code of the Philippines).
  • Grace Period: Six months for disclosures before filing, aligning with global standards.
  • Patent Term: 20 years from filing date.
  • Patent Examination: Substantive examination required; delays sometimes extend patent grant timelines.
  • Compulsory Licensing: Allowed under public health emergencies, which can impact patent exclusivity.
  • Patentability Criteria: Novelty, inventive step, and industrial application are mandatory; claims must be clear and supported by data.

Key Takeaways

  • Scope & Claims: Patent PH12017502092 likely protects specific chemical entities, formulations, or processes used in treating particular diseases in the Philippines.
  • Landscape: The Philippine patent environment reflects global trends, with strong competition from international patents, especially in oncology, infectious diseases, and biologics.
  • Legal & Policy Environment: Clear patentability parameters and potential for compulsory licensing influence strategic patent filing and enforcement.

FAQs

1. Can patent PH12017502092 be challenged for invalidity?
Yes, by demonstrating prior art, lack of novelty, or obviousness, stakeholders can challenge the patent through legal procedures at IPOPHL.

2. How long does it take to get a patent granted in the Philippines?
Typically, 3-5 years from filing, depending on examination delays and patent prosecution strategies.

3. Are there restrictions on patenting biological or natural substances in the Philippines?
Biological and natural substances are patentable if they meet criteria for novelty and inventive step, but naturally occurring substances per se are generally non-patentable unless altered or purified significantly.

4. Does the Philippines recognize patent term adjustments or extensions?
No, the standard patent term is 20 years from filing. There are no extensions for pharmaceuticals unless under specific government programs.

5. How does patent enforcement occur in the Philippines?
Through civil litigation, including injunctions, damages, and administrative actions. Enforcement can be challenging due to resource constraints and procedural hurdles.


References

  1. Philippine Intellectual Property Office. (2023). Patent Laws and Guidelines. https://www.ipophil.gov.ph
  2. World Intellectual Property Organization. (2022). Patent Landscape Reports. https://www.wipo.int
  3. ASEAN Patent Examination Guidelines. (2021). Regional patent practices. https://asean.org
  4. Philippine Republic Act No. 8293 (Patent Law). (1997). https://lawphil.net/statutes/repacts/ra1997/ra_8293_1997.html
  5. PCT Applicant. (2022). Patent filing procedures in the Philippines. https://www.wipo.int/pct/en/filing/philippines.html

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.